Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors reducing the potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
This summer, the Company signed a Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry ("Sinopharm-CSIPI"), the leader among all pharmaceutical research institutes in China, and Sinopharm A-THINK Pharmaceutical Co., Ltd. ("Sinopharm A-THINK"), the only injectable anti-tumor drug research and development, manufacture and distribution integrated platform within Sinopharm Group.
The purpose of the MOU is to negotiate a licensing agreement to bring their flagship drug, PV-10 to the Chinese market. We spoke to Provectus' COO and CFO, Peter Culpepper on this latest approach.
The company CFO participated in a Q&A session regarding a PVCT move into the Chinese market. Read about that and analyst comments here:
http://bit.ly/-PVCT-AnalystBrief
Copy and paste to browser may be required.
About Small Cap Traders
Once you have read our reports written by financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties.
3rd party financial analysts provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Forward-Looking Disclaimer
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the analyst report.
If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
Contact: [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/provectus-biopharmaceuticals-looks-at-the-asian-markets-analyst-coverage-by-small-cap-traders-687382421.html
SOURCE Small Cap Traders
Share this article